NKTR
NEKTAR THERAPEUTICS
Next earnings Aug 5, 2026 (after close) · consensus $-2.08 EPS, $10.6M rev
Last earnings -2.0% on 2026-05-07
$63.65
▲ +2.61%$63.65▲ +567.19%
over 1Y
L $9.54EODHDH $100.35
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.6%
1W-3.1%
1M-2.7%
3M-7.3%
YTD+46.6%
1Y+567.2%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Revenue fell -43.9% YoY.
Revenue (FY2025) $55.2M · FY2025
NEKTAR THERAPEUTICS shows $55.2M in FY2025 revenue (-43.9% YoY), a -297.1% net margin, and -182.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $102M | $92.1M | $90.1M | $98.4M | $55.2M |
| Gross profit | — | — | — | — | — |
| Operating income | -$446M | -$376M | -$264M | -$105M | -$140M |
| Net income | -$524M | -$368M | -$276M | -$119M | -$164M |
| Diluted EPS | -$2.86 | -$1.97 | -$1.45 | -$8.68 | -$9.73 |
| Net margin | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.81B
EV / EBITDA—
EV / Sales32.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-9.0%
FCF yield-11.4%
Quality & risk
ROIC (est.)-123.2%
Free cash flow-$209M
Total debt—
Net cash$15.1M
Altman Z-Score-13.57 distress
Piotroski F-Score2/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY-84.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-152026-06-17open ↗144Filing2026-06-17open ↗144Filing2026-06-16open ↗144Filing2026-06-15open ↗8-KPeriod ending 2026-06-052026-06-05open ↗3Period ending 2026-05-152026-05-26open ↗4Period ending 2026-05-192026-05-21open ↗4Period ending 2026-05-192026-05-21open ↗144Filing2026-05-19open ↗144Filing2026-05-19open ↗SCHEDULE 13G/AFiling2026-05-15open ↗
Frequently asked
- Is NEKTAR THERAPEUTICS (NKTR) a buy?
- NKTR currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Revenue fell -43.9% YoY.
- What is NEKTAR THERAPEUTICS's quality score?
- NKTR scores 28.09803921568627/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000906709, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 6:20:15 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.